1.Treatment outcome and prognosis of head and neck hemangiopericytoma.
Alimujiang WUSHOU ; Xinchao MIAO ; Yajun ZHAO
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2014;28(23):1855-1859
OBJECTIVE:
Aim of the study is to report the unique clinicopathologic feature, treatment outcome and prognostic factors of head and neck hemangiopericytoma (HNHPC).
METHOD:
A retrospective data collection of reported HNHPC cases, in which therapy, follow-up and outcome data were available, was performed from the electronic database of PubMed, Embase, Google scholar, China National Knowledge Infrastructure, Wan Fang and Wei Pu until on December 31, 2013.
RESULT:
A total of 213 HNHPC cases were identified from 122 peer-reviewed articles. The recurrence rate was 24.4% (51/209). The positive surgical margin (OR= 3. 977, P<0. 01) and poor pathologic differentiation (OR=l. 890, P<0. 01) were associated with increased local recurrence. The metastasis rate was 15.8% (22/139). The positive surgical margin (OR=13. 833, P<0. 01), poor pathologic differentiation (OR=4. 661, P<0. 01) and non-surgical treatment (OR=2. 000, P<0. 01) were associated with increased distant metastasis. The mortality rate was 15. 0% (32/213). The tumor size >5. 0 cm in diameter (OR= 2. 860, P<0. 05), positive surgical margin (OR=9. 833, P<0. 01), poor pathologic differentiation (OR=4. 061, P<0. 01) and non-surgical treatment (OR=2. 032, P<0. 01) were associated with worse mortality. The treatment included surgery alone 139 cases, multiple treatments 64 cases and non-surgical treatment 10 cases. The overall survival (OS) of the 213 cases was 85%, and the 3-year, 5-year and 10-year OS were 86%, 78% and 74%, respectively. The 3-year, 5-year and 10-year OS for surgery alone were 95%, 88% and 84%, respectively. The 3- year, 5-year and 10-year OS for surgery plus radiotherapy were 90%, 80% and 80%, respectively. The 3-year, 5- year and 10-year OS for surgery plus chemotherapy were 75%, 25% and 25%, respectively. The 3-year, 5-year and 10-year OS for surgery plus radio-chemotherapy were 67%, 58% and 46%, respectively. There were signifi- cant survival difference in recurrence-free survival (RFS), metastasis free survival (MFS) and OS depending on surgical margins (P<0. 01). RFS, MFS and OS difference were identified depending on pathologic differentiation (P<0. 01). MFS and OS differences were observed on the different treatment modality (P<0. 01). OS differences was observed on the different tumor sizes (P<0. 05). Positive surgical margins was correlated with disease recurrence (HR= 3. 680, P<0.01), while poor pathologic differentiation was correlated with metastasis and death (HR=2. 619, P<0. 05 and HR=3. 188, P<0. 05). The tumor size >5. 0 cm in diameter and non-surgical treatment was correlated with death (HR= 5. 461, P<0. 01 and HR= 8. 563, P<0. 01, respectively).
CONCLUSION
The surgical resection was the mainstream treatment and it was superior to multiple treatments. The tumor size, surgical margins, pathological differentiation and non-surgical treatment were independent prognostic factors.
Head and Neck Neoplasms
;
mortality
;
pathology
;
therapy
;
Hemangiopericytoma
;
mortality
;
pathology
;
therapy
;
Humans
;
Neoplasm Recurrence, Local
;
Prognosis
;
Retrospective Studies
;
Treatment Outcome
2.Clinical analysis of 23 primary sinonasal malignant melanoma.
Ying WANG ; Bing GUAN ; Li XU ; Ying XU ; Junzhong ZHANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2014;28(20):1559-1561
OBJECTIVE:
To review the pathological and clinical features and treatment of sinonasal malignant melanoma.
METHOD:
A retrospective analysis of 23 cases of sinonasal malignant melanoma. All the patients were conformed by histopathology, the most common symptoms were nasal obstruction and epistexis. Eight cases were treated with surgery, 8 with surgery and radiotherapy, 5 with surgery and chemotherapy, 2 with surgery and ra- diotherapy plus chemotherapy.
RESULT:
Twenty patients were followed up, the survival rates of 3 and 5 years were 50% (10/20) and 35% (7/20), respectively.
CONCLUSION
Sinonasal malignant melanoma has an aggressive behavior and easy recurrence and poor prognosis. Early diagnosis and reasonable treatment can increase the survival rate of the disease.
Humans
;
Melanoma
;
mortality
;
pathology
;
therapy
;
Nasal Obstruction
;
Neoplasm Recurrence, Local
;
Nose Neoplasms
;
mortality
;
pathology
;
therapy
;
Paraganglioma
;
Paranasal Sinus Neoplasms
;
mortality
;
pathology
;
therapy
;
Retrospective Studies
;
Survival Rate
3.Review of clinical investigation on recurrence of gastric cancer following curative resection.
Jing-hui LI ; Shi-wu ZHANG ; Jing LIU ; Ming-zhe SHAO ; Lin CHEN
Chinese Medical Journal 2012;125(8):1479-1495
OBJECTIVETo discuss the present status and progress of clinical research on recurrence of gastric cancer after surgery, including patterns, clinicopathologic factors, prognosis, detection, diagnosis, prevention, and treatment strategies.
DATA SOURCESThe data used in this review were mainly from PubMed articles published in English from 2000 to August 2011. The search terms were "gastric cancer" and "recurrence".
STUDY SELECTIONArticles were selected if they involved clinicopathologic factors, detection methods, and treatment strategies of recurrence of gastric cancer.
RESULTSPeritoneal recurrence is the most common pattern in recurrence of gastric cancer. The main risk factors for recurrence of gastric cancer are tumor stage, including depth of tumor invasion and lymph node metastasis, and Borrmann classification. The prognosis of patients with recurrence is very poor, especially patients with peritoneal recurrence. Systemic chemotherapy is still the main treatment method for patients with recurrent cancer. If complete resection can be accomplished, some benefits may be obtained from surgery for recurrence. However, standard treatment for patients with recurrence has not yet been established.
CONCLUSIONSEarly detection and diagnosis of recurrence is quite crucial for treatment and prognosis. The optimal therapeutic strategy for recurrence should be based on a multidisciplinary assessment and the patient's individual state and should involve combined therapy.
Biomarkers, Tumor ; analysis ; Humans ; Neoplasm Recurrence, Local ; diagnosis ; rehabilitation ; surgery ; therapy ; Neoplasm Staging ; Prognosis ; Stomach Neoplasms ; diagnosis ; mortality ; pathology ; surgery
4.Twenty-four cases of carcinoma in pleomorphic adenoma in the salivary gland.
Cai-ping HUANG ; Hong-shi WANG ; Xiao-yu TU
Chinese Journal of Oncology 2003;25(1):91-93
OBJECTIVETo study the clinical characteristics, treatment and prognosis 24 cases of carcinoma in pleomorphic adenoma in salivary gland.
METHODSThe clinical data of 24 patients with carcinoma in pleomorphic adenoma treated in our hospital from September 1974 to July 1995 were analyzed.
RESULTSThe overall 5-year survival rate was 66.7%. The five-year survival rates of patients with carcinoma in pleomorphic adenoma in the major and minor salivary glands were 63.6% and 2/2, respectively.
CONCLUSIONOperation is the optimal treatment and extensive resection at the initial operation is suggested. For lumps in the submaxillary gland, preventive neck dissection should be considered. Postoperative radiotherapy can not improve the local-control rate.
Adenoma, Pleomorphic ; diagnosis ; mortality ; therapy ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Prognosis ; Salivary Gland Neoplasms ; mortality ; pathology ; therapy ; Survival Rate
5.Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.
Jeongshim LEE ; Sung Soo AHN ; Jong Hee CHANG ; Chang Ok SUH
Yonsei Medical Journal 2018;59(2):194-201
PURPOSE: To evaluate the adequacy of retreatment, including hypofractionated re-irradiation (HFReRT), after surgery for recurrent glioblastoma (GBM) and related prognosticators of outcomes. MATERIALS AND METHODS: From 2011 to 2014, 25 consecutive patients with recurrent (n=17) or secondary (n=7) disease underwent maximal surgery and subsequent HFReRT after meeting the following conditions: 1) confirmation of recurrent or secondary GBM after salvage surgery; 2) Karnofsky performance score (KPS) ≥60; and 3) interval of ≥12 months between initial radiotherapy and HFReRT. HFReRT was delivered using a simultaneous integrated boost technique, with total dose of 45 Gy in 15 fractions to the gross tumor volume (GTV) and 37.5 Gy in 15 fractions to the clinical target volume. RESULTS: During a median follow-up of 13 months, the median progression-free and overall survival (OS) were 13 and 16 months, respectively. A better KPS (p=0.026), no involvement of the eloquent area at recurrence (p=0.030), and a smaller GTV (p=0.005) were associated with better OS. Additionally, OS differed significantly between risk groups stratified by the National Institutes of Health Recurrent GBM Scale (low-risk vs. high-risk, p=0.025). Radiologically suspected radiation necrosis (RN) was observed in 16 patients (64%) at a median of 9 months after HFReRT, and 8 patients developed grade 3 RN requiring hospitalization. CONCLUSION: HFReRT after maximal surgery prolonged survival in selected patients with recurrent GBM, especially those with small-sized recurrences in non-eloquent areas and good performance.
Adult
;
Brain Neoplasms/mortality/pathology/*therapy
;
Dose Hypofractionation
;
Female
;
Glioblastoma/mortality/pathology/*therapy
;
Humans
;
Karnofsky Performance Status
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality/pathology/*therapy
;
Prognosis
;
*Radiosurgery
;
Re-Irradiation/*methods
;
Salvage Therapy/methods
;
Survival Rate
;
Treatment Outcome
6.Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion.
Haider MAHDI ; Amelia JERNIGAN ; Benjamin NUTTER ; Chad MICHENER ; Peter G ROSE
Journal of Gynecologic Oncology 2015;26(3):208-213
OBJECTIVE: To investigate the rate, predictors of lymph node metastasis (LNM) and pattern of recurrence in clinically early stage endometrial cancer (EC) with positive lymphovascular space invasion (LVSI). METHODS: Women with clinically early stage EC and positive LVSI 2005 to 2012 were identified. Kaplan-Meier curves and logistic regression models were used. RESULTS: One hundred forty-eight women were identified. Of them, 25.7% had LNM (21.7% pelvic LNM, 18.5% para-aortic LNM). Among patients with LNM who had both pelvic and para-aortic lymphadenectomy, isolated pelvic, para-aortic and both LNM were noted in 51.4%, 17.1%, and 31.4% respectively. Age and depth of myometrial invasion were significant predictors of LNM in LVSI positive EC. Node positive patients had high recurrence rate (47% vs. 11.8%, p<0.05) especially distant (60.9% vs. 7.9%, p<0.001) and para-aortic (13.2% vs. 1.8%, p=0.017) recurrences compared to node negative EC. LNM was associated with lower progression-free survival (p=0.002) but not overall survival (p=0.73). CONCLUSION: EC with positive LVSI is associated with high risk of LNM. LNM is associated with high recurrence rate especially distant and para-aortic recurrences. Adjuvant treatments should target prevention of recurrences in these areas.
Aged
;
Chemoradiotherapy, Adjuvant
;
Disease-Free Survival
;
Endometrial Neoplasms/mortality/*pathology/therapy
;
Female
;
Humans
;
Lymph Node Excision/mortality
;
Lymphatic Metastasis
;
Middle Aged
;
Neoplasm Invasiveness
;
Neoplasm Recurrence, Local/mortality/*pathology/therapy
;
Retrospective Studies
;
Treatment Outcome
7.Postmastectomy radiotherapy for early breast cancer.
Shulian WANG ; Yexiong LI ; Zihao YU
Chinese Journal of Oncology 2002;24(1):68-70
OBJECTIVETo investigate the value of postmastectomy radiotherapy for early breast cancer.
METHODSFrom 1983 to 1991, 605 patients with T1-2N0-1M0 breast cancer were treated by radical mastectomy in our hospital. 149 patients underwent surgery alone(S group), and the remaining 456 patients received further adjuvant treatment. Of these patients, 135 received postoperative radiotherapy(S + R group), 113 adjuvant chemotherapy or tamoxifen(S + Y group), and 208 adjuvant chemotherapy or tamoxifen plus radiotherapy(S + Y + R group). Here, chemotherapy plus tomoxifen is designated as systematically therapy. The locoregional recurrence (LRR), disease-free survival (DFS), and overall survival (OS) rates were calculated by Kaplan-Meier analysis. The differences in locoregional recurrence and survival between these groups were compared by logrank test.
RESULTSThe 10-year actuarial LRR, OS and DFS rates for all patients were 13.4%, 81.6%, and 67.6%, respectively. The 10-year LRR rate was 10.3% for patients with negative axillary nodes, 9.4% for those with 1-3 positive nodes, and 25.9% for those with four or more positive nodes. The locoregional recurrence was significantly higher in patients with four or more positive nodes as compared to those with negative or 1-3 positive nodes (P < 0.05). For the S and S + R groups, the 10-year actuarial LRR rate was 18.7% in the S group and 7.5% in the S + R group (P = 0.017), the corresponding OS and DFS rates of these two groups were 82.1% and 81.1% (P = 0.618), and 65.2% and 71.6% (P = 0.457), respectively. For the S + Y and S + Y + R groups, the 10-year actuarial LRR rate was 21.1% in the S + Y group and 9.5% in the S + Y + R group (P = 0.001), There, the corresponding OS and DFS rates were 75.5% and 85.0% (P = 0.020), and 59.3% and 70.2% (P = 0.003), respectively. Only for patients with four or more positive nodes who had had systematic therapy, radiotherapy was beneficial; the 10-year actuarial LRR of patients who received systematic therapy only was 40.1% as compared with 15.1% of those who received systematic therapy plus radiotherapy; Their OS rates were 55.4% and 67.1% (P = 0.040) and their DFS rates were 30.5% and 57.3% (P = 0.001).
CONCLUSIONPost-mastectomy radiotherapy is able to significantly decrease the locoregional recurrence and improve the survival of patients with four or more positive axillary nodes. We suggest that postmastectomy radiotherapy be given as routine for these patients.
Adult ; Aged ; Breast Neoplasms ; mortality ; pathology ; radiotherapy ; surgery ; Combined Modality Therapy ; Female ; Humans ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Postoperative Care ; Survival Rate
8.Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
Hyung Suk KIM ; Ja Hyeon KU ; Se Joong KIM ; Sung Joon HONG ; Sung Hoo HONG ; Hong Sup KIM ; Tae Gyun KWON ; Jin Seon CHO ; Seong Soo JEON ; Kwan Joong JOO ; Han Jong AHN ; Hong Seok PARK ; Do Hwan SEONG ; Dong Deuk KWON ; Hyung Jin KIM ; Jae Sung LIM ; Hyung Lae LEE
Yonsei Medical Journal 2016;57(4):855-864
PURPOSE: To identify the prognostic factors related to tumor recurrence and progression in Korean patients with non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Data were collected and analyzed for 2412 NMIBC patients from 15 centers who were initially diagnosed after transurethral resection of bladder tumor (TURBT) from January 2006 to December 2010. Using univariable and multivariable Cox proportional hazards models, the prognostic value of each variable was evaluated for the time to first recurrence and progression. RESULTS: With a median follow-up duration of 37 months, 866 patients (35.9%) experienced recurrence, and 137 (5.7%) experienced progression. Patients with recurrence had a median time to the first recurrence of 10 months. Multivariable analysis conducted in all patients revealed that preoperative positive urine cytology (PUC) was independently associated with worse recurrence-free survival [RFS; hazard ratio (HR) 1.56; p<0.001], and progression-free survival (PFS; HR 1.56; p=0.037). In particular, on multivariable analysis conducted for the high-risk group (T1 tumor/high-grade Ta tumor/carcinoma in situ), preoperative PUC was an independent predictor of worse RFS (HR 1.73; p<0.001) and PFS (HR 1.96; p=0.006). On multivariable analysis in patients with T1 high-grade (T1HG) cancer (n=684), better RFS (HR 0.75; p=0.033) and PFS (HR 0.33; p<0.001) were observed in association with the administration of intravesical Bacillus Calmette-Guérin (BCG) induction therapy. CONCLUSION: A preoperative PUC result may adversely affect RFS and PFS, particularly in high-risk NMIBC patients. Of particular note, intravesical BCG induction therapy should be administered as an adjunct to TURBT in order to improve RFS and PFS in patients with T1HG cancer.
Aged
;
Carcinoma in Situ/*mortality/*pathology/therapy
;
Disease Progression
;
Disease-Free Survival
;
Female
;
Humans
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/*mortality/*pathology
;
Prognosis
;
Proportional Hazards Models
;
Republic of Korea
;
Retrospective Studies
;
Risk
;
Urinary Bladder Neoplasms/*mortality/*pathology/therapy
9.Effect of progesterone combined with chemotherapy on epithelial ovarian cancer.
Chinese Medical Journal 2003;116(3):388-391
OBJECTIVETo identify an effective auxiliary therapy for epithelial ovarian cancer.
METHODSProgesterone acetate given at 250 mg intramuscularly twice a week for 1 month followed by increased administration to 500 mg intramuscularly every two weeks for 3 years was used in combination with platinum based chemotherapy to treat patients with epithelial ovarian cancer as a first-line therapy. Prognoses of the patients receiving progesterone combined with chemotherapy (progesterone group) and those receiving chemotherapy only (control group) were compared.
RESULTSThree-year recurrence and survival conditions of the progesterone and control groups were as follows. Stage Ia: no patient relapsed or died in either group. Stage Ib-Ic: three-year recurrence rates were 14.2% and 37.5%, respectively (P = 0.2845); three-year survival rates were 92.3% and 87.5% (P = 0.7221). Stage II: 1 patient relapsed and died among the 3 patients in the progesterone group; among the 4 patients in the control group, 1 patient relapsed, none died. Stage III: three-year recurrence rates were 30.8% and 64.3%, respectively (P = 0.1170); three-year survival rates were 85.7% and 42.9%, respectively (P = 0.005). Stage IV: 4 patients relapsed and 1 patient died among the 7 patients in the progesterone group; both the patients in the control group relapsed and died.
CONCLUSIONSThe results indicated that progesterone combined with platinum based chemotherapy as a first-line therapy may improve the prognosis of advanced epithelial ovarian cancer, but would not change the prognosis of early stage epithelial ovarian cancer.
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; administration & dosage ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial ; drug therapy ; mortality ; pathology ; Ovarian Neoplasms ; drug therapy ; mortality ; pathology ; Progesterone ; administration & dosage ; Survival Rate
10.Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand.
Siriwan TANGJITGAMOL ; Jakkapan KHUNNARONG ; Sunamchok SRIJAIPRACHAROEN
Journal of Gynecologic Oncology 2015;26(4):293-302
OBJECTIVE: To evaluate the prevalence and features of non-endometrial cancers in Thai endometrial cancer (EC) patients. METHODS: EC patients treated in our institution were identified and the following data were collected: age, EC stage, histopathology, adjuvant therapy, other cancers, living status, and cause of death. RESULTS: The mean age of the 344 patients was 56.8+/-10.8 years. Fifty (14.5%) had other synchronous and metachronous cancers. Mean ages of the patients with or without other cancers were not significantly different, 55.7+/-10.04 years versus 57.1+/-11.0 years, respectively (p=0.358). History of any cancer in the family and tumor in the lower uterine segment were more frequent among the patients with other cancers (6.0% vs. 1.7%, p=0.095; 12.0% vs. 1.0%, p<0.001; respectively). Six patients had > or =2 other cancers. Ovarian, breast, and colon were the three most common other cancers. After a median follow-up of 57.1 months, 18.3% of patients had died: 30.0% of patients with other cancers and 16.3% of those without other cancers. The corresponding EC deaths were 14.0% and 11.2%. The 5-year overall survival was significantly lower in patients who had other cancers: 79.3% (95% confidence interval [CI], 68.3 to 90.3) vs. 86.0% (95% CI, 81.7 to 90.3) than in those without (p=0.023). However, the corresponding disease-specific survival was not significantly different: 85.1% (95% CI, 75.5 to 94.7) compared with 89.0% (95% CI, 85.1 to 92.9), respectively (p=0.514). CONCLUSION: Thai EC patients had a high incidence of other cancers. Overall survival of EC patients who had other cancers was worse than those without, while disease-specific survival was not significantly different.
Breast Neoplasms/mortality/pathology/therapy
;
Chemotherapy, Adjuvant/methods
;
Colonic Neoplasms/mortality/pathology/therapy
;
Disease-Free Survival
;
Endometrial Neoplasms/mortality/*pathology/therapy
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality
;
Neoplasms, Multiple Primary/mortality/*pathology/therapy
;
Neoplasms, Second Primary/mortality/*pathology/therapy
;
Radiotherapy, Adjuvant/methods
;
Tertiary Care Centers/statistics & numerical data
;
Thailand/epidemiology